These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 18411770)

  • 1. [Efficacy and safety of propiverine on improvement of symptoms and QOL for female patients with wet overactive bladder].
    Kato M; Matsukawa Y; Kato K; Kondo A; Yamada S; Hattori R; Gotoh M
    Hinyokika Kiyo; 2008 Mar; 54(3):165-71. PubMed ID: 18411770
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Propiverine hydrochloride improved correlatively subjective QOL and objective findings in Japanese patients with urinary frequency and/or incontinence].
    Noguchi K; Yamagishi T; Suzuki K; Kondo K; Kishida T; Saito K; Sekiguchi Y; Nakaigawa N; Ogawa T; Uemura H; Yao M; Kubota Y; Kawai M; Okajima K; Kobayashi K; Moriyama M; Kinoshita Y; Mikata K; Kitami K; Masuda M; Saito R; Murai T; Tomoda T; Noguchi S; Sakai N; Hamano A; Nomura S; Sato K
    Hinyokika Kiyo; 2006 May; 52(5):343-8. PubMed ID: 16758722
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The elderly patient with urge incontinence or urge-stress incontinence - efficacy and cardiac safety of propiverine].
    Dorschner W; Stolzenburg JU; Griebenow R; Halaska M; Brünjes R; Frank M; Wieners F
    Aktuelle Urol; 2003 Mar; 34(2):102-8. PubMed ID: 14566693
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of fesoterodine and tolterodine in patients with overactive bladder.
    Chapple CR; Van Kerrebroeck PE; Jünemann KP; Wang JT; Brodsky M
    BJU Int; 2008 Nov; 102(9):1128-32. PubMed ID: 18647298
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Urinary urgency outcomes after propiverine treatment for an overactive bladder: the 'Propiverine study on overactive bladder including urgency data'.
    Lee KS; Lee HW; Choo MS; Paick JS; Lee JG; Seo JT; Lee JZ; Lee YS; Yoon H; Park CH; Na YG; Jeong YB; Lee JB; Park WH
    BJU Int; 2010 Jun; 105(11):1565-70. PubMed ID: 19912183
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlation between improvements in Overactive Bladder Symptom Score and health-related quality of life questionnaires in overactive bladder patients treated with an antimuscarinic drug.
    Kubota Y; Kojima Y; Shibata Y; Imura M; Kohri K; Sasaki S
    Neurourol Urodyn; 2011 Sep; 30(7):1309-14. PubMed ID: 21560155
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Efficacy and safety of imidafenacin in female patients with urge and mixed urinary incontinence].
    Shimada M; Inoue K; Okumura T; Aoki S; Ogawa Y; Matsubara E; Maeda T; Ogawa Y; Sasaki H
    Hinyokika Kiyo; 2011 Jan; 57(1):1-6. PubMed ID: 21304252
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized, double-blind, placebo- and propiverine-controlled trial of the once-daily antimuscarinic agent solifenacin in Japanese patients with overactive bladder.
    Yamaguchi O; Marui E; Kakizaki H; Itoh N; Yokota T; Okada H; Ishizuka O; Ozono S; Gotoh M; Sugiyama T; Seki N; Yoshida M;
    BJU Int; 2007 Sep; 100(3):579-87. PubMed ID: 17669143
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment with propiverine in children suffering from nonneurogenic overactive bladder and urinary incontinence: results of a randomized placebo-controlled phase 3 clinical trial.
    Marschall-Kehrel D; Feustel C; Persson de Geeter C; Stehr M; Radmayr C; Sillén U; Strugala G
    Eur Urol; 2009 Mar; 55(3):729-36. PubMed ID: 18502028
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Propiverine hydrochloride immediate and extended release: comparison of efficacy and tolerability in patients with overactive bladder.
    Jünemann KP; Hessdörfer E; Unamba-Oparah I; Berse M; Brünjes R; Madersbacher H; Gramatté T
    Urol Int; 2006; 77(4):334-9. PubMed ID: 17135784
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Naftopidil and propiverine hydrochloride for treatment of male lower urinary tract symptoms suggestive of benign prostatic hyperplasia and concomitant overactive bladder: a prospective randomized controlled study.
    Yokoyama T; Uematsu K; Watanabe T; Sasaki K; Kumon H; Nagai A;
    Scand J Urol Nephrol; 2009; 43(4):307-14. PubMed ID: 19396723
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy, tolerability and safety of propiverine hydrochloride in comparison to oxybutynin in children with urge incontinence due to overactive bladder: Results of a multicentre observational cohort study.
    Alloussi S; Mürtz G; Braun R; Gerhardt U; Heinrich M; Hellmis E; Horn W; Marschall-Kehrel D; Niklas K; Raabe M; Rössler T; Seibt B; Siemer S; Schultz-Lampel D; Walter H; Wiedeking B; Alloussi S; Bock P; Strugala G; Madersbacher H
    BJU Int; 2010 Aug; 106(4):550-6. PubMed ID: 20002668
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of fesoterodine on quality of life: pooled data from two randomized trials.
    Kelleher CJ; Tubaro A; Wang JT; Kopp Z
    BJU Int; 2008 Jul; 102(1):56-61. PubMed ID: 18564231
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Propiverine hydrochloride in Japanese patients with overactive bladder: a randomized, double-blind, placebo-controlled trial.
    Gotoh M; Yokoyama O; Nishizawa O;
    Int J Urol; 2011 May; 18(5):365-73. PubMed ID: 21332825
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Electromotive drug-administration: a pilot study for minimal-invasive treatment of therapy-resistant idiopathic detrusor overactivity.
    Bach P; Wormland RT; Möhring C; Goepel M
    Neurourol Urodyn; 2009; 28(3):209-13. PubMed ID: 19205067
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sustained improvement in patient-reported outcomes during long-term fesoterodine treatment for overactive bladder symptoms: pooled analysis of two open-label extension studies.
    Kelleher CJ; Dmochowski RR; Berriman S; Kopp ZS; Carlsson M
    BJU Int; 2012 Aug; 110(3):392-400. PubMed ID: 22129365
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Does alpha1-blocker provide additional improvement of quality-of-life in patients with overactive bladder?--a multi-center prospective randomized trial between anti-cholinergic (propiverine chloride) with and without alpha1-blocker (urapidil)].
    Matsuyama H; Shimizu Y; Kamiryo Y; Joko K; Shimabukuro T; Suga A; Takemoto M; Imoto K; Hara Y; Yamamoto N; Kaneda Y; Harada N; Naito K
    Nihon Hinyokika Gakkai Zasshi; 2007 May; 98(4):604-13. PubMed ID: 17564103
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy, tolerability and safety of propiverine hydrochloride in children and adolescents with congenital or traumatic neurogenic detrusor overactivity--a retrospective study.
    Grigoleit U; Mürtz G; Laschke S; Schuldt M; Goepel M; Kramer G; Stöhrer M
    Eur Urol; 2006 Jun; 49(6):1114-20; discussion 1120-1. PubMed ID: 16542772
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Long-term administration study of propiverine hydrochloride (BUP-4 tablets) in pollakiuria and urinary incontinence].
    Noguchi K; Masuda M; Noguchi S; Kubota Y; Hosaka M; Senga Y; Sano K; Miyai K; Kanno H; Kitami K; Fujinami K; Miura T; Kondo I; Kawasaki C; Moriyama M; Hara Y; Ida T; Fukuoka H; Nakagawa J; Kitajima N; Fukuda M; Satomi Y; Takahashi T; Yamaguchi T; Shiozaki H
    Hinyokika Kiyo; 1998 Sep; 44(9):687-93. PubMed ID: 9805679
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term safety, tolerability, and efficacy of the novel anti-muscarinic agent imidafenacin in Japanese patients with overactive bladder.
    Homma Y; Yamaguchi O
    Int J Urol; 2008 Oct; 15(11):986-91. PubMed ID: 18761536
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.